Eiger BioPharmaceuticals, Inc. financial data

Symbol
EIGRQ on OTC
Location
2155 Park Boulevard, Palo Alto, CA
Fiscal year end
December 31
Former names
Celladon Corp (to 3/23/2016)
Latest financial report
10-K - Q4 2023 - Apr 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 235 % -54.3%
Quick Ratio 8.23 % -13.6%
Debt-to-equity 672 % +808%
Return On Equity -870 % -650%
Return On Assets -113 % -69.1%
Operating Margin -688 % -8.54%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.48M shares -96.6%
Common Stock, Shares, Outstanding 1.48M shares +0.7%
Entity Public Float 30M USD -89.1%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 1.48M shares +6.39%
Weighted Average Number of Shares Outstanding, Diluted 1.48M shares +6.39%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 3.21M USD -20.3%
Cost of Revenue 115K USD -90.7%
Research and Development Expense 62.3M USD -17.2%
Costs and Expenses 87.6M USD -17.6%
Operating Income (Loss) -71.8M USD +22.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -75M USD +22.5%
Income Tax Expense (Benefit) 6K USD -73.9%
Net Income (Loss) Attributable to Parent -75M USD +22.5%
Earnings Per Share, Basic -50.8 USD/shares +27.2%
Earnings Per Share, Diluted -50.8 USD/shares +27.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.4M USD -1.39%
Cash, Cash Equivalents, and Short-term Investments 39.4M USD -67.4%
Inventory, Net 1.56M USD -45.5%
Assets, Current 37.8M USD -67.8%
Property, Plant and Equipment, Net 627K USD -9.91%
Operating Lease, Right-of-Use Asset 209K USD -15%
Other Assets, Noncurrent 360K USD -81.1%
Assets 38.8M USD -67.7%
Accounts Payable, Current 2.12M USD -76.4%
Accrued Liabilities, Current 9.97M USD -36.3%
Liabilities, Current 53.3M USD +112%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 53.3M USD -17.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -169K USD +43.7%
Retained Earnings (Accumulated Deficit) -512M USD -17.1%
Stockholders' Equity Attributable to Parent -14.5M USD -126%
Liabilities and Equity 38.8M USD -67.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24M USD -30%
Net Cash Provided by (Used in) Financing Activities 41K USD -99.9%
Net Cash Provided by (Used in) Investing Activities 13.4M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 1.48M shares +0.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -10.6M USD -144%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 25.4M USD -1.39%
Interest Paid, Excluding Capitalized Interest, Operating Activities 920K USD +34.1%
Deferred Tax Assets, Valuation Allowance 117M USD +21.2%
Deferred Tax Assets, Gross 117M USD +21%
Operating Lease, Liability 205K USD -26.5%
Payments to Acquire Property, Plant, and Equipment 216K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -74.8M USD +22.8%
Lessee, Operating Lease, Liability, to be Paid 209K USD -26.4%
Property, Plant and Equipment, Gross 1.8M USD +12.9%
Operating Lease, Liability, Current 84K USD -82.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 84K USD -27%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure +43.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4K USD -20%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 69.4M USD +10.1%
Unrecognized Tax Benefits 5.28M USD +51.1%
Operating Lease, Payments 200K USD 0%
Depreciation, Depletion and Amortization 74K USD +1.37%
Deferred Tax Assets, Net of Valuation Allowance 21K USD -83.6%
Share-based Payment Arrangement, Expense 5.01M USD -39.8%
Interest Expense 5.47M USD +32.3%